Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase (Q44605528)

From Wikidata

Jump to navigation Jump to search

scientific article published on December 1, 2003

Language	Label	Description	Also known as
English	Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase	scientific article published on December 1, 2003

Statements

scholarly article

1 reference

Europe PubMed Central

4 December 2017

Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase (English)

1 reference

Europe PubMed Central

4 December 2017

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

interferon alfa

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

10.1038/SJ.LEU.2403158

https://api.crossref.org/works/10.1038/SJ.LEU.2403158

17 March 2024

1

object named as

S. Branford

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14523461

17 March 2024

author name string

Z. Rudzki

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14523461

17 March 2024

A. Harper

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14523461

17 March 2024

A. Grigg

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14523461

17 March 2024

K. Taylor

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14523461

17 March 2024

S. Durrant

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14523461

17 March 2024

C. Arthur

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14523461

17 March 2024

P. Browett

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14523461

17 March 2024

A. P. Schwarer

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14523461

17 March 2024

D. Ma

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14523461

17 March 2024

J. F. Seymour

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14523461

17 March 2024

K. Bradstock

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14523461

17 March 2024

D. Joske

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14523461

17 March 2024

K. Lynch

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14523461

17 March 2024

I. Gathmann

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14523461

17 March 2024

T. P. Hughes

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14523461

17 March 2024

language of work or name

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14523461

17 March 2024

publication date

1 December 2003

1 reference

Europe PubMed Central

4 December 2017

full work available at URL

https://www.nature.com/articles/2403158.pdf

Portable Document Format

online access status

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14523461

17 March 2024

https://www.nature.com/articles/2403158.pdf

Portable Document Format

1 reference

10.1038/SJ.LEU.2403158

https://api.crossref.org/works/10.1038/SJ.LEU.2403158

17 March 2024

https://www.nature.com/articles/2403158

1 reference

10.1038/SJ.LEU.2403158

https://api.crossref.org/works/10.1038/SJ.LEU.2403158

17 March 2024

1 reference

Europe PubMed Central

4 December 2017

17

1 reference

Europe PubMed Central

4 December 2017

2401-2409

1 reference

Europe PubMed Central

4 December 2017

12

1 reference

Europe PubMed Central

4 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403158

0 references

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403158

21 January 2018

Acute leukaemia in bcr/abl transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403158

21 January 2018

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403158

21 January 2018

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403158

21 January 2018

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403158

21 January 2018

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403158

21 January 2018

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403158

21 January 2018

Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403158

21 January 2018

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403158

21 January 2018

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403158

21 January 2018

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403158

21 January 2018

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403158

21 January 2018

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403158

21 January 2018

Molecular monitoring of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403158

21 January 2018

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403158

21 January 2018

The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403158

21 January 2018

Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403158

21 January 2018

Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403158

21 January 2018

Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403158

21 January 2018

Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403158

21 January 2018

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403158

21 January 2018

Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403158

21 January 2018

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403158

21 January 2018

bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403158

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403158

7 January 2021

based on heuristic

inferred from DOI database lookup

Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403158

7 January 2021

based on heuristic

inferred from DOI database lookup

Polymerase chain reaction for detection of residual leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403158

7 January 2021

based on heuristic

inferred from DOI database lookup

The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403158

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2403158

1 reference

Europe PubMed Central

4 December 2017

1 reference

Europe PubMed Central

4 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44605528&oldid=2104786315"